WO1996034290A1 - Etalons d'hemoglobine - Google Patents

Etalons d'hemoglobine Download PDF

Info

Publication number
WO1996034290A1
WO1996034290A1 PCT/GB1996/000975 GB9600975W WO9634290A1 WO 1996034290 A1 WO1996034290 A1 WO 1996034290A1 GB 9600975 W GB9600975 W GB 9600975W WO 9634290 A1 WO9634290 A1 WO 9634290A1
Authority
WO
WIPO (PCT)
Prior art keywords
haemoglobin
glycosylated
complex
reference material
standard reference
Prior art date
Application number
PCT/GB1996/000975
Other languages
English (en)
Inventor
Erling Sundrehagen
Frank Frantzen
Original Assignee
Axis Biochemicals A/S
Dzieglewska, Hanna, Eva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axis Biochemicals A/S, Dzieglewska, Hanna, Eva filed Critical Axis Biochemicals A/S
Publication of WO1996034290A1 publication Critical patent/WO1996034290A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin

Definitions

  • Blood samples to be determined are reacted with Drabkin' s solution (containing K 3 Fe(CN)6, KCN and NaHC0 3 to lyse the cells and convert haemoglobin in the sample to cyanmethaemoglobin and the resulting absorbance is read and compared against the cyanmethaemoglobin standard.
  • Drabkin' s solution containing K 3 Fe(CN)6, KCN and NaHC0 3 to lyse the cells and convert haemoglobin in the sample to cyanmethaemoglobin and the resulting absorbance is read and compared against the cyanmethaemoglobin standard.
  • Carbonmonoxy haemoglobin the complex of non- glycosylated haemoglobin with carbon monoxide, or carboxy haemoglobin as it is also termed, is known and the interaction between carbon monoxide and haemoglobin has been studied; carbon monoxide binds reversibly to haem in a manner almost identical to oxygen but with significantly higher affinity, thereby displacing oxygen from oxyhaemoglobin. Carbon monoxide is not readily displaced from haemoglobin except at high oxygen tension. It is therefore a serious poison. In normal, non-smoking individuals, levels of carbonmonoxy haemoglobin in the blood are very low. In heavy smokers, the levels may rise to up to 8-9% saturation of haemoglobin with carbon monoxide .
  • the standard reference material comprises up to 50% glycosylated haemoglobin (relative to total haemoglobin) , preferably 1 to 15% glycosylated haemoglobin.
  • haemoglobin preparations are susceptible to oxidation and precautions should be taken during the various processing steps, including washing and incubation steps etc. to avoid or minimise such unwanted side reactions.
  • Reagents should therefore preferably be used with the lowest possible metal ion contents, and chelating agents eg. EDTA, may beneficially be added.
  • Autoxidation also increases at high temperature, at low pH and in the presence of high salt concentrations. It is therefore best for such conditions to be avoided, particularly during the more prolonged glycosylation steps.
  • ligands which may bind to haemoglobin and cause spectral shifts, for example azide, fluoride and cyanate ions etc .
  • a reagent comprising a signal-forming molecule comprising a conjugate of one or more dihydroxyboryl residues or salts thereof linked to a signal-forming label
  • the means for separation of the haemoglobin may conveniently comprise a selective precipitating agent, such as metallic cations, especially zinc ions, organic solvents or haemoglobin-specific antibodies as described in WO 90/13818.
  • a selective precipitating agent such as metallic cations, especially zinc ions, organic solvents or haemoglobin-specific antibodies as described in WO 90/13818.
  • GHb level recorded: 8.8%. Methaemoglobin level increases approximately by 2%.
  • Centrifugation step - remove plasma.
  • the blood is filled in centrifugation vials of 50 ml. Centrifuge at 3000 rpm (1500 rcf) for 10 minutes at 5°C.
  • LAF-bench glassware baked at 90-100°C for 2 hours, plastics washed with 70% alcohol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur un complexe d'hémoglobine glycosylée à l'aide d'un ligand pouvant servir d'étalon de référence pour déterminer la concentration de l'hémoglobine glycosylée. Le ligand du complexe déplace l'oxygène de l'oxyhémoglobine glycosylée et se fixe au fragment haem de l'hémoglobine pour empêcher l'oxydation du Fe?2+ en Fe3+¿, et cela sans pratiquement modifier le spectre d'absorption de l'oxyhémoglobine glycosylée.
PCT/GB1996/000975 1995-04-24 1996-04-24 Etalons d'hemoglobine WO1996034290A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9508278.0 1995-04-24
GBGB9508278.0A GB9508278D0 (en) 1995-04-24 1995-04-24 Haemoglobin standards

Publications (1)

Publication Number Publication Date
WO1996034290A1 true WO1996034290A1 (fr) 1996-10-31

Family

ID=10773417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/000975 WO1996034290A1 (fr) 1995-04-24 1996-04-24 Etalons d'hemoglobine

Country Status (2)

Country Link
GB (1) GB9508278D0 (fr)
WO (1) WO1996034290A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110339A1 (fr) * 2005-04-08 2006-10-19 Streck Laboratories, Inc. TEMOINS CELLULAIRES POUR LA DETERMINATION DE L'HEMOGLOBINE GLYQUEE A1c
CN111024959A (zh) * 2019-12-20 2020-04-17 深圳市蔚景生物科技有限公司 一种稳定的蛋白质溶液、其制备方法及检测试剂盒
CN113959807A (zh) * 2021-10-26 2022-01-21 上海瀚诺威生物科技有限公司 一种糖化血红蛋白校准质控品的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0271996A1 (fr) * 1986-11-18 1988-06-22 Scripps Clinic And Research Foundation Méthode immunochimique de détermination d'hémoglobine glycosylée stable
WO1990013818A1 (fr) * 1989-05-11 1990-11-15 Axis Research As PROCEDE DE MESURE DE L'HEMOGLOBINE GLUCOSYlEE
WO1992008984A1 (fr) * 1990-11-14 1992-05-29 Axis Research As Analyse pour proteines du sang glucosees

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0271996A1 (fr) * 1986-11-18 1988-06-22 Scripps Clinic And Research Foundation Méthode immunochimique de détermination d'hémoglobine glycosylée stable
WO1990013818A1 (fr) * 1989-05-11 1990-11-15 Axis Research As PROCEDE DE MESURE DE L'HEMOGLOBINE GLUCOSYlEE
WO1992008984A1 (fr) * 1990-11-14 1992-05-29 Axis Research As Analyse pour proteines du sang glucosees

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110339A1 (fr) * 2005-04-08 2006-10-19 Streck Laboratories, Inc. TEMOINS CELLULAIRES POUR LA DETERMINATION DE L'HEMOGLOBINE GLYQUEE A1c
US7361513B2 (en) 2005-04-08 2008-04-22 Streck, Inc. Cellular controls for glycated hemoglobin Hb A1c
CN111024959A (zh) * 2019-12-20 2020-04-17 深圳市蔚景生物科技有限公司 一种稳定的蛋白质溶液、其制备方法及检测试剂盒
CN113959807A (zh) * 2021-10-26 2022-01-21 上海瀚诺威生物科技有限公司 一种糖化血红蛋白校准质控品的制备方法
CN113959807B (zh) * 2021-10-26 2024-09-17 上海瀚诺威生物科技有限公司 一种糖化血红蛋白校准质控品的制备方法

Also Published As

Publication number Publication date
GB9508278D0 (en) 1995-06-14

Similar Documents

Publication Publication Date Title
Lubran The measurement of total serum proteins by the Biuret method
Mitchell et al. Enzyme and hemoglobin retention in human erythrocyte stroma
AU652092B2 (en) Immunological method for the determination of a haemoglobin derivative
US5589393A (en) Method for preparing a glycated hemoglobin solution
US5468640A (en) Cyanide-free hemoglobin reagent
KR100601272B1 (ko) 산화환원반응을 이용한 측정방법
US8921052B2 (en) Hemoglobin derivative measurement method, and reagent composition, measurement kit, analysis device and analysis system for use in the method
JPH0812196B2 (ja) グリコシル化ヘモグロビンのアッセイ
US4686181A (en) Specific binding assay employing anti-G6PDH as label
US5284777A (en) Combined glycated hemoglobin and immunoturbidometric glycated albumin assay from whole blood lysate
CA1199257A (fr) Dosage de l'hemoglobine glycosylee
JP2000210100A (ja) 酸化還元反応を用いた測定方法
FI88546B (fi) Nytt foerfarande foer bestaemning av stabilt glukohemoglobin
FI102698B (fi) Menetelmä ja testausjärjestelmä hemoglobiinin Alc:n määrittämiseksi
WO1996034290A1 (fr) Etalons d'hemoglobine
Hara et al. Immunoassay using a metal-complex compound as a chemiluminescent catalyst. I. Iron (III) phthalocyanine as a labeling reagent.
EP3923806B1 (fr) Dispositifs d'étalonnage et contrôles pour la détermination du pourcentage d'hémoglobine glyquée dans un échantillon liquide de test de patient
AU742373B2 (en) Competitive apo-peroxidase assay
JP3181390B2 (ja) タンパク質の糖化割合の測定方法
US11300577B1 (en) Turbidity normalization algorithm and methods of reducing intralipid/lipemia interference in hemoglobin A1c assays
EP0195320B1 (fr) Essai diagnostique utilisant la microperoxidase
Deeg et al. A new approach to photometry of glycated hemoglobin in human blood.
JPH0658936A (ja) 糖化蛋白の測定方法
JPH0783921A (ja) 糖化蛋白の測定方法
JPH0743363A (ja) 糖化蛋白質の分析法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase